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A report on ‘Genomes to Systems’, the Fourth Conference
of the Consortium for Post-Genome Science, Manchester,
UK, 17-19 March 2008.
The Consortium for Post-Genome Science promotes the
application of research advances in genomics, transcrip-
tomics and proteomics to advance our understanding of
biological systems. For this information to be useful to the
wider scientific community, informatics tools are required
for the assimilation and modeling of these systems. The
latest Genomes to Systems (G2S) conference [http://www.
genomestosystems.org] highlighted recent advances in these
areas, with a focus on contemporary technologies in
biotechnology, biomedicine and their applications to
understanding integrated systems in both normal and
disease states.
T Th he e   s se ea ar rc ch h   f fo or r   d di is se ea as se e   m ma ar rk ke er rs s
Early diagnosis of cancer dramatically increases survival rate
and because of this, biomarker discovery studies seek to
identify early-onset markers. Samir Hanash (Fred
Hutchinson Cancer Research Center, Seattle, USA) and
Ruedi Aebersold (ETH, Zurich, Switzerland and Institute for
Systems Biology, Seattle, USA) highlighted the importance
of rigorous large-scale quantitative data acquisition to
facilitate the search for disease biomarkers. This was a
contrast to previous meetings, which tended to put the
emphasis on improving proteomics strategies and data-
analysis tools. The primary stumbling block in biomarker
discovery appears to be the amount and quality of the data
being analyzed. Specifically, Hanash described techniques
for discovering biological indicators of cancer in plasma
samples, using both human and murine models. Of
particular interest was a study aimed at identifying bio-
markers for breast cancer using a biobank of plasma samples
obtained from women over a ten year period. The Biobank
contains samples from over 160,000 women and is being
used specifically to look for biomarkers in 1,000 women in
samples taken a year prior to diagnosis of breast cancer.
Aebersold also highlighted the challenges associated with
defining disease biomarkers and performing hypothesis-
driven research. He noted that disease markers are often
different for disease subtypes and dependent on associated
risk factors, and that these must be identified amid all the
biological ‘noise’. Different diseases may also perturb over-
lapping regions of networks and disease-specific signatures
of these deregulated networks need to be identified and used
for biomarker discovery. Andrey Rzhetsky (University of
Chicago, USA) presented methods of text mining that should
go some way to help distinguish when a single factor is
contributing to multiple diseases. Specifically, he gave exam-
ples of gene targets contributing to autism, bipolar disorder
and schizophrenia, predicting gene candidates that are both
specific to these diseases and shared among them. The topic
of multiple disease factors for a given disease was taken
further by John Griffiths (Cancer Research UK, Cambridge,
UK), whose findings in tumor cells indicate that a multi-
target approach (using combinations of two or more drugs)
will in all likelihood be necessary to control progression of
diseases such as cancer and diabetes. He reported that
inhibition of tumor growth was found to be markedly
improved when the histone deacetylase inhibitors SAHA and
LAQ824 were used in combination.
Several compelling cases of disease-specific genomic markers
involved in responses to drugs were presented. Epilepsy can
present in multiple forms, with different patients exhibiting
a different pattern of resistance and response to therapeutic
agents. Sanjay Sisodiya (University College London, UK)
presented data showing that mutation of the gene SCN1A,
which encodes a sodium channel, is associated with drug-
resistant forms of epilepsy. On the same theme, Caroline Lee(National University of Singapore, Singapore) reported a
combination of three single-nucleotide polymorphisms in
the blood-brain barrier transporter MDR1 that can be used
as a marker of Parkinson’s disease among ethnic Chinese,
and Ann Daly (Newcastle University, UK) reported the
characterization of specific genetic polymorphisms in genes
encoding the enzymes UGT2B7, CYP2C8 and ABCC2,
associated with hepatotoxicity induced by the non-steroidal
anti-inflammatory drug Diclofenac.
S Sy ys st te em ms s   b bi io ol lo og gy y   a an nd d   p pr ro ot te eo om mi ic cs s
One of the most important aspects of systems biology is
translating the biological information into models that can
be manipulated and used in simulations. The Systems
Biology Markup Language (SBML) [http://sbml.org], a
computer-readable format for representing biological
models, has been evolving over the past eight years with the
input of users and software developers. Mike Hucka (Cali-
fornia Institute of Technology, Pasadena, USA) described
the current status of SBML and developments soon to be
implemented. Rather than further complicating an already
over-extended system, SBML is being modularized, so that
biochemical species can themselves be annotated, with
localization, substructures and post-translational modifica-
tions defined, instead of having to specify different biological
states of the same protein as separate entities. 
Having defined the language of computational modeling,
Nicolas Le Novère (European Bioinformatics Institute,
Hinxton, UK) defined the ‘minimum information
requested in the annotation of biochemical models’
(MIRIAM) [http://www.ebi.ac.uk/compneur-srv/miriam]
- guidelines for the curation of quantitative models that
can be used by the systems biology community. Le Novere
continued by defining the ‘minimum information about a
simulation experiment’ (MIASE), guidelines enabling the
research community to repeat and make use of previous
simulations of a given model. An overview of COPASI (a
COmplex Pathway SImulator) software for the modeling,
simulation and analysis of biological systems was given by
Ursula Kummer (University of Heidelberg, Germany).
COPASI [http://www.copasi.org/tiki-index.php] has been
developed by Kummer and colleagues in collaboration with
Pedro Mendes (University of Manchester, UK), as a user-
friendly, platform-independent tool for the analysis of
biochemical networks. 
Hiroaki Kitano (Systems Biology Institute, Tokyo, Japan)
gave an entertaining presentation on the graphical repre-
sentation of biological networks. Unlike engineers, who
have specific graphical expressions for representing defined
functions and/or species, the bioscience community uses
the same graphical notation for different biological
processes. Kitano described the use of the standardized
systems biology graphical notation (SBGN)
[http://www.sbgn.org] for biological pathways, which
essentially generates a biological circuit diagram. While the
widespread use of a standard notation of this sort would be
extremely useful for the bioscience community, making
biological network diagrams visually transparent, only time
will tell how quickly it will filter into general use.
Several presentations focused on evaluating and developing
novel techniques for X-ray crystallography and NMR to help
improve analysis of protein structure and function. Using
X-ray crystallography to understand protein function can
lead to the discovery of new therapeutic agents, as
demonstrated by Larry DeLucas (University of Alabama,
Birmingham, USA) and Stephen Cusack (EMBL, Grenoble,
France). DeLucas presented novel crystallographic
techniques for studying drug design based on analyzing the
structures of the proteins the drugs are intended to target.
He described the application of self-interaction
chromatography (SIC) to measure protein-protein
interactions, using this technique to facilitate structure-
based drug design. He also demonstrated that certain
additives, such as polysaccharides and amino acids, can lead
to the preferential precipitation of certain protein species
without prior separation, due to changes in hydrophobicity.
A reduction in growth rate was also found to improve the
quality of crystals for structural analysis. Cusack described
how structural elucidation of the influenza virus polymerase
can help to understand viral transcription mechanisms.
Using a library-based screening technique called ‘expression
of soluble proteins by random incremental truncation’
(ESPRIT), he has elucidated the structure of the polymerase
subunit PB2 and defined specific regions of the protein
involved in nuclear import and mRNA cap-binding.
Elucidation of these motifs has helped define the mechanism
of transcription of viral mRNAs. In addition, modeling
studies in the presence and absence of viral mRNAs were
used to define areas of interest that may be targeted for
antiviral drug design.
Many presentations focused on the adaptation and develop-
ment of established techniques to understand more of the
proteome. Simon Gaskell (University of Manchester, UK)
described how complementary methods of tandem mass
spectrometry (MS/MS) can be exploited to gain more raw
data from proteomics samples. Fragmentation of a given
peptide ion was induced using both collision-induced
dissociation and electron transfer dissociation, techniques
that differ significantly in their mechanisms of
fragmentation and thus generate different types of fragment
ions. Sequential fragmentation in this manner increases the
dimensionality of the acquired data and enables deeper
mining of the proteome. He echoed the need for
quantitative proteomics data for biological systems, and
discussed recent developments for the absolute
quantification of sites of protein phosphorylation using a
modified QconCAT-based strategy. QconCAT permits the
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manner, and was developed in a collaboration between
Gaskell and Rob Beynon (University of Liverpool, UK).
Coding sequences for the peptides being used as
quantification standards are concatenated for expression as
a single artificial protein in Escherichia coli. The QconCAT
protein can then be isotopically labeled, purified and
quantified as a single entity, prior to proteolysis and the
generation of more than 50 purified stoichiometric
reference peptides in a single step. The advantages of
QconCAT over synthetic peptide production for the
absolute quantification of proteins in complex mixtures,
namely the ease and cost-effectiveness, were also discussed
by Beynon. Also raised was the need to examine the extent
of analyte digestion in order to accurately determine
absolute amounts of proteins. 
Simon Hubbard (University of Manchester, UK) discussed
the selection of peptides for use as standards for absolute
protein quantification in a semi-automated fashion. A
combinatorial approach employing three independent
machine-learning methods has been developed that
predicts those tryptic methods most likely to ‘fly’ (that is,
ionize and be detected) during liquid chromatography-mass
spectrometry (LC/MS) analysis, with a positive predictive
value of greater than 79%. Hubbard also discussed new
bioinformatics tools under development, including open-
source software for extracting quantitative data from a
variety of proteomics platforms, currently called the
SILACanalyzer and described the updated peptide
identification database PepSeekerGOLD [http://www.
ispider.manchester.ac.uk/pepseeker]. Pepseeker has so far
been used to help elucidate peptide-fragmentation
mechanisms in different types of mass spectrometer and as
a tool to predict sites of trypsin hydrolysis. Beynon
presented a strategy for simplifying analyses using
positional, rather than shotgun, proteomics, which involve
enriching for and analyzing amino-terminal peptides. Using
this strategy, free amines at the protein amino terminus and
lysine side chains are chemically blocked, the sample is
trypsinized and peptides containing free amine groups
(present at the newly generated peptide amino termini) are
removed. Quantification using only the amino-terminal
peptide was shown to give similar data to those obtained
with multiple peptides, arguing against the requirement for
large-scale peptide analysis. 
Anne Dell (Imperial College London, UK) discussed the
analysis of glycosylated proteins, drawing attention to the
Consortium for Functional Glycomics, which has recently
developed a database of glycan structures and glycan-
binding proteins [http://www.functionalglycomics.org] as a
tool to interpret MS data in a semi-automated fashion. She
also explained how knowledge of the biosynthetic pathways
of glycans is critical for interpreting MS data and gave
examples of how glycan signatures might be used as
diagnostic markers in cancer. She also explained how
knowledge of the biosynthetic pathways of glycans is critical
for interpreting MS data and used the altered glycosylation
status of haptoglobin in the sera of patients with prostate
cancer as an example of how specific glycan signatures
might be used as diagnostic markers in cancer.
The conference culminated in a plenary lecture by Hans
Westerhoff (University of Manchester, UK and Vrije
Universiteit, Amsterdam), discussing how the study of
biological systems as networks could be used to identify
therapeutic drug targets. The multifactorial nature of
diseases means that their treatment should be considered in
the context of the networks that are perturbed. Importantly,
therefore, drugs that target the most ‘fragile’ part of the
perturbed network might be the most physiologically
relevant. As an extension to this, he also suggested that
drugs for parasitic infections are likely to have reduced host
toxicity if they are targeted to factors where the parasite and
host have different fragility coefficients. Furthermore, when
considering drug targets and toxicity, it is important to
realize that points of robustness change in normal versus
tumor cells, and that it is the difference of these fragility
coefficients that is likely to lead to the development of
successful novel therapeutics. The 2008 Genomes to
Systems conference provided a stimulating environment to
discuss the (multiple) current, and future, directions of
systems biology research and we look forward to the next
meeting in this series.
A Ac ck kn no ow wl le ed dg ge em me en nt ts s
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